Literature DB >> 12151306

Lipid-mediated delivery of oligonucleotide to pulmonary endothelium.

Zheng Ma1, Junlan Zhang, Sean Alber, John Dileo, Yoichi Negishi, Donna Stolz, Simon Watkins, Leaf Huang, Bruce Pitt, Song Li.   

Abstract

Pulmonary endothelium plays an important role in the maintenance of normal pulmonary physiology and its dysfunction is involved in a number of pulmonary diseases. Correction of endothelial dysfunction via antisense oligodeoxyonucleotides (ODN) is dependent on the development of a delivery vehicle that can efficiently deliver the ODN to pulmonary endothelium with minimal toxicity. To this end, we have developed a lipidic vector (LPD) that is composed of 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) liposomes, protamine, and ODN. This formulation is highly efficient in delivering ODN to the lung via the vascular route. The efficiency of delivery is a function of lipid composition and of the charge ratio between lipid and ODN. Immunofluorescence staining of BrdU-labeled ODN suggested efficient accumulation of ODN in the alveolar capillary region. Transmission electron microscopy of immunogold localization of BrdU-labeled ODN confirmed that pulmonary endothelial cells were indeed targeted by the vector. Furthermore, this formulation is associated with minimal proinflammatory cytokine response and other hematologic toxicities when the ODN lack a potent unmethylated CpG motif. Pretreatment of mice with LPD containing an ODN against intercellular adhesion molecule-1 (ICAM-1) significantly decreased ICAM-1 expression in the lung following LPS challenge. These results provide a basis for lipid-mediated delivery of ODN for the treatment of pulmonary diseases.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12151306     DOI: 10.1165/ajrcmb.27.2.4653

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  6 in total

1.  Activation of TNFR1 ectodomain shedding by mitochondrial Ca2+ determines the severity of inflammation in mouse lung microvessels.

Authors:  David J Rowlands; Mohammad Naimul Islam; Shonit R Das; Alice Huertas; Sadiqa K Quadri; Keisuke Horiuchi; Nilufar Inamdar; Memet T Emin; Jens Lindert; Vadim S Ten; Sunita Bhattacharya; Jahar Bhattacharya
Journal:  J Clin Invest       Date:  2011-04-25       Impact factor: 14.808

Review 2.  Targeted delivery of nucleic-acid-based therapeutics to the pulmonary circulation.

Authors:  Ramalinga Kuruba; Annette Wilson; Xiang Gao; Song Li
Journal:  AAPS J       Date:  2009-01-09       Impact factor: 4.009

Review 3.  Delivery of oligonucleotides with lipid nanoparticles.

Authors:  Yuhua Wang; Lei Miao; Andrew Satterlee; Leaf Huang
Journal:  Adv Drug Deliv Rev       Date:  2015-02-27       Impact factor: 15.470

Review 4.  Recent Developments in mRNA-Based Protein Supplementation Therapy to Target Lung Diseases.

Authors:  Itishri Sahu; A K M Ashiqul Haque; Brian Weidensee; Petra Weinmann; Michael S D Kormann
Journal:  Mol Ther       Date:  2019-03-06       Impact factor: 11.454

5.  Drug nanocarriers labeled with near-infrared-emitting quantum dots (quantoplexes): imaging fast dynamics of distribution in living animals.

Authors:  Arkadi Zintchenko; Andrei S Susha; Massimo Concia; Jochen Feldmann; Ernst Wagner; Andrey L Rogach; Manfred Ogris
Journal:  Mol Ther       Date:  2009-08-25       Impact factor: 11.454

6.  Inflammatory monocyte/macrophage modulation by liposome-entrapped spironolactone ameliorates acute lung injury in mice.

Authors:  Wen-Jie Ji; Yong-Qiang Ma; Xin Zhang; Li Zhang; Yi-Dan Zhang; Cheng-Cheng Su; Guo-An Xiang; Mei-Ping Zhang; Zhi-Chun Lin; Lu-Qing Wei; Peizhong P Wang; Zhuoli Zhang; Yu-Ming Li; Xin Zhou
Journal:  Nanomedicine (Lond)       Date:  2016-05-12       Impact factor: 5.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.